ArticleJAMA dermatology2022
Analysis of Specialist and Patient Perspectives on Strategies to Improve Cardiovascular Disease Prevention Among Persons With Psoriatic Disease.
Article in JAMA dermatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 28 citations in OpenAlex.
- Trial
- Construction of risk prediction models for psoriasis based on 45 dietary nutrients using machine learning and SHAP analysis.Asia Pacific journal of clinical nutrition · 2026Article
- GLP-1RAs and cardiovascular risk reduction in psoriasis: A retrospective cohort study.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Article
- Patient awareness and perception of cardiovascular risk in rheumatic and musculoskeletal diseases: results from an international survey.EULAR rheumatology open · 2026Article
- Improving Cardiovascular Outcomes in the Psoriasis Cohort. Psoriasis and Cardiovascular Disease-Clinician Knowledge, Practice and Perceptions.The Australasian journal of dermatology · 2025Review
- Positive associations between triglyceride-glucose (TyG) and TyG-body mass index (TyG-BMI) with cardiovascular disease in patients with psoriasis: cross-sectional results from the SPEECH.Frontiers in immunology · 2025Article
- Clinical characteristics and influencing factors of cardiovascular comorbidities in psoriasis.Frontiers in cardiovascular medicine · 2025Article
- A diagnostic prediction model for cardiovascular diseases (CVDs) in patients with psoriasis.Frontiers in cardiovascular medicine · 2025Article
- Addressing Cardiovascular Risk in People With Psoriatic Disease Using a Care Coordinator Model: A Qualitative Analysis of a Pilot Study.Journal of psoriasis and psoriatic arthritis · 2024Article
- Characterization of cardiometabolic risk awareness among patients with psoriasis: A quality improvement survey study.JAAD international · 2024Article
- Using Guidelines of Care to Lower Cardiovascular Risk in Patients with Psoriasis.Dermatologic clinics · 2024Review
- A Care Coordination Model to Prevent Cardiovascular Events in Patients with Psoriatic Disease: A Multicenter Pilot Study.The Journal of investigative dermatology · 2024Article
- Impact of GLP-1 Receptor Agonists on Psoriasis and Cardiovascular Comorbidities: A Narrative Review.Psoriasis (Auckland, N.Z.) · 2024Review
- Cardiovascular Considerations and Implications for Treatment in Psoriasis: An Updated Review.Vascular health and risk management · 2024Review
- Cardiovascular Screening Practices and Statin Prescription Habits in Patients with Psoriasis among Dermatologists, Rheumatologists and Primary Care Physicians.Acta dermato-venereologica · 2023Article
- Biologics for Reducing Cardiovascular Risk in Psoriasis Patients.Journal of clinical medicine · 2023Review
- Psoriasis and Cardiovascular Disease-An Ounce of Prevention Is Worth a Pound of Cure.JAMA dermatology · 2022Article
Corrections and comments
- Commented on by
Authors and funding
9 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
importancePatients with psoriatic disease are at increased risk of cardiovascular disease (CVD), which is a leading cause of mortality in this population. However, many of these patients do not have an active relationship with a primary care physician, and there may be a role for specialist-led care in prevention of CVD.
objectiveTo explore clinician and patient perspectives regarding strategies to improve CVD prevention via specialist-led care. DESIGN, SETTING, AND
participantsUsing electronically collected surveys, a best-worst scaling experimental survey study was conducted among dermatologists through the National Psoriasis Foundation as well as the American Academy of Dermatology from October 27, 2020, to April 1, 2021, to rank the strategies according to their potential to improve CVD prevention among patients with psoriatic disease. Participants were asked about the feasibility of specialist-led screening through an electronically delivered survey from the National Psoriasis Foundation conducted between February 1 and April 21, 2021. Patients with psoriatic disease were asked about whether they would like the specialist to screen for CVD risk factors. In addition, patients reported their likelihood to engage in CVD risk screening and management behaviors in scenarios in which either the primary care physician or specialist was making the recommendations. MAIN OUTCOMES AND MEASURES: For the clinician surveys, the primary outcome was the ratio scaled preference score (range, 0-100; higher is more preferred), as well as whether they think calculating a 10-year CVD risk score and prescribing statins seems feasible. For the patient surveys, the primary outcome was the likelihood to check cholesterol level, incorporate diet and exercise, or use statin therapy depending on whether recommended by the specialist or primary care physician, whether they would like their specialist to educate them about CVD risk, and whether they would find it convenient to have their cholesterol level checked by their specialist.
resultsAmong 183 dermatologists (102 [55.7%] women; mean [SD] age not collected), clinical decision support (preference score, 22.3; 95% CI, 20.7-24.0), patient education (preference score, 14.1; 95% CI, 12.5-15.7), and clinician education (preference score, 15.8; 95% CI, 14.3-17.3) were ranked as strategies likely to improve CVD prevention in patients with psoriatic disease. In addition, 69.3% (95% CI, 62.2%-76.0%) of dermatologists agreed or strongly agreed that checking lipid levels was feasible. Among 160 patients with psoriasis and 162 patients with psoriatic arthritis (226 [70.2%] women; mean [SD] age, 54 [13.3] years), patients reported they were as likely to engage in cardiovascular risk screening and management behaviors whether recommended by their primary care physician or their specialist. In addition, 60.0% (95% CI, 52.0%-67.7%) of patients with psoriasis and 75.3% (95% CI, 67.9%-81.7%) of those with psoriatic arthritis agreed that it would be convenient for them to have their cholesterol checked by their dermatologist/rheumatologist. CONCLUSIONS AND RELEVANCE: In this survey study, dermatologists and patients with psoriatic disease expressed positive perspectives about engaging in a specialist-led model of care to improve CVD prevention. Dermatologists appear to view several strategies as having potential to improve cardiovascular risk prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.